ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

A Multicenter, Randomized, Controlled Trial to Steer Immunosuppressive Therapy by Virus-Specific T Cells after Pediatric Kidney Transplantation (IVIST-Trial)

T. Ahlenstiel-Grunow1, A. Großhennig1, R. Schild2, J. Oh2, C. Taylan3, L. Weber3, H. Staude4, M. Verboom1, C. Schröder1, R. Sabau1, A. Koch1, X. Liu1, L. Pape1

1Hannover Medical School, Hannover, Germany, 2University Hospital Hamburg-Eppendorf, Hamburg, Germany, 3University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany, 4University Hospital of Rostock, Rostock, Germany

Meeting: 2020 American Transplant Congress

Abstract number: 1

Keywords: Glomerular filtration rate (GFR), Immunosuppression, Kidney transplantation, Pediatric

Session Information

Session Name: Plenary Session I

Session Type: Plenary Session

Date: Saturday, May 30, 2020

Session Time: 9:57am-10:40am

 Presentation Time: 10:00am-10:07am

Location: Main Channel

*Purpose: Pharmakokinetic monitoring of immunosuppressants alone is insufficient to estimate the individual intensity of immunosuppression after kidney transplantation (Tx). Virus-specific T cells (Tvis) correlate with virus-specific as well as with general cellular immune defense. Additional steering by Tvis level may optimize dosing of immunosuppressants (effect-related drug monitoring).

*Methods: In an investigator-initiated, multicenter, prospective trial, 64 pediatric kidney recipients (mean age 10.8 ± 4.2 yrs; ♂ 57.8%) were randomized 4 weeks after Tx either to a non-intervention group (n=33) with classical trough level monitoring of immunosuppressants or to an intervention group (n=31) with additional steering by Tvis levels. Tvis against cytomegalovirus, adenovirus and herpes simplex virus were quantified by intracellular cytokine staining followed by flow cytometry. Both groups received the same immunosuppressive regimen consisting of cyclosporine A (CsA) and everolimus (Eve) with the same target range of trough levels. The primary endpoint was the estimated glomerular filtration rate (eGFR) two years after Tx.

*Results: Two years after Tx, we observed an increase of eGFR from 55.0 ± 17.5 (baseline) to 60.7 ± 22.8 mL/min/1.73 m2 in the intervention group and no substantial difference in the control group (from 61.5 ± 21.3 to 59.6 ± 22.3 mL/min/1.73 m2). The respective mean difference (intervention-control) was 7.52 ± 27.61 mL/min/1.73 m2. As the variability of eGFR was larger than assumed, this difference was not statistically significant. We additionally observed several benefits on secondary endpoints for patients in the intervention group. They received lower daily doses of Eve (0.8 ± 0.3 vs. 1.2 ± 0.5 mg/m2, t-test p=0.004) and CsA (78.4 ± 20.0 vs. 88.4 ± 26.5 mg/m2, t-test p=0.13) resulting in lower trough levels of Eve (3.5 ± 0.7 vs. 4.5 ± 0.8 µg/L, t-test p <0.0001) and CsA (47.4 ± 9.9 vs. 64.1 ± 11.1 µg/L, t-test p<0.0001). Fewer patients in the intervention group received glucocorticoids (20% vs. 47%, χ²-test p=0.038) two years after Tx. Patients in the non-intervention group had a higher risk for rejections (logrank p=0.0786) and EBV viremia (logrank p=0.0896). Donor-specific antibodies were detected in 8 patients of the intervention and 9 of the control group. Numbers of adverse and serious adverse events were comparable.

*Conclusions: Additional steering of immunosuppressive therapy by Tvis levels is safe and personalizes immunosuppressive therapy by reducing exposure to immunosuppressants, resulting in stabilization of eGFR and reduced risk for rejection and EBV viremia.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Ahlenstiel-Grunow T, Großhennig A, Schild R, Oh J, Taylan C, Weber L, Staude H, Verboom M, Schröder C, Sabau R, Koch A, Liu X, Pape L. A Multicenter, Randomized, Controlled Trial to Steer Immunosuppressive Therapy by Virus-Specific T Cells after Pediatric Kidney Transplantation (IVIST-Trial) [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/a-multicenter-randomized-controlled-trial-to-steer-immunosuppressive-therapy-by-virus-specific-t-cells-after-pediatric-kidney-transplantation-ivist-trial/. Accessed May 10, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences